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Mutations in MED12 Cause X-Linked Ohdo Syndrome
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Ohdo syndrome comprises a heterogeneous group of disorders characterized by intellectual disability (ID) and typical facial features,
including blepharophimosis. Clinically, these blepharophimosis-ID syndromes have been classified in five distinct subgroups, including
the Maat-Kievit-Brunner (MKB) type, which, in contrast to the others, is characterized by X-linked inheritance and facial coarsening at
older age. We performed exome sequencing in two families, each with two affected males with Ohdo syndrome MKB type. In the two
families, MED12 missense mutations (c.3443G>A [p.Arg1148His] or c.3493T>C [p.Ser1165Pro]) segregating with the phenotype were
identified. Upon subsequent analysis of an additional cohort of nine simplex male individuals with Ohdo syndrome, one additional
de novo missense change (c.5185C>A [p.His1729Asn]) inMED12 was detected. The occurrence of three different hemizygous missense
mutations in three unrelated families affected by Ohdo syndromeMKB type shows thatmutations inMED12 are the underlying cause of
this X-linked form of Ohdo syndrome. Together with the recently described KAT6Bmutations resulting in Ohdo syndrome Say/Barber/
Biesecker/Young/Simpson type, our findings point to aberrant chromatin modification as being central to the pathogenesis of Ohdo
syndrome.Ohdo syndrome (MIM 249620) comprises a heterogeneous
group of disorders characterized by intellectual disability
(ID) and typical facial features, including blepharophimo-
sis, ptosis, a round face with a characteristic nose, and
a narrow mouth.1 These blepharophimosis-ID syndromes
have been classified in five distinct subgroups. The first
group can be distinguished from the others because it is
caused by deletions of the short arm of chromosome 3.
The second group is designated as Ohdo type on the basis
of the original report by Ohdo et al.1,2 These persons
present with typical features of prognathism, short phil-
trum, and proteinuria, whereas hypotonia, abnormal
growth, and limb defects are lacking. The Verloes type
is a more severe condition with severe microcephaly,
epilepsy, brain malformations, adducted thumbs, and
abnormal genitals.1 The most clinically distinctive pheno-
type is the Say/Barber/Biesecker/Young/Simpson (SBBYS)
type (MIM 603736), which is characterized by striking
facial dysmorphisms that include a large to bulbous nasal
tip; small and/or dysplastic, thick, simple, or overfolded
pinnae; thick swollen cheeks; and retrognathia. In
addition, hypotonia, hyperextensible joints, cryptorchi-
dism, and a wide range of congenital malformations are
present.1,3 This type was recently shown to be caused by
mutations in lysine acetyltransferase 6B (KAT6B [MIM
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which, in contrast to the other types, is characterized by
X-linked inheritance and facial coarsening with thick
alae nasi and a triangular face at older age,1 is caused by
mutations in MED12.
Exome sequencing was performed in two individuals
from two families affected by Ohdo syndrome MKB
type (Figure 1 and Table S1, available online). This study
was approved by the institutional review board Commis-
sie Mensgebonden Onderzoek Regio Arnhem-Nijmegen.
Written informed consent was obtained for all individuals
participating in this study. The first family showed a clear
X-linked inheritance pattern with two affected males in
two generations and has been reported previously.1,10
The second family comprised two affected brothers. In
both families, 250k NspI SNP array analysis (Affymetrix,
Santa Clara, CA, USA) revealed no significant chromosome
aberrations. Analysis of the X-chromosome-inactivation
status via methylation-sensitive PCR and fragment-length
analysis of the androgen-receptor CAG repeat polymor-
phism11 showed a nonrandom pattern of X inactivation
in individual II:2 from family 1 and individual I:2 from
family 2 (in >90% of the cells, the alleles submitted
to the sons were inactive). In family 2, mutation analysis
of FOXL2 (MIM 605597) did not show any abnormali-
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Figure 1. Overview of Clinical and Genetic Data of Families Affected by Ohdo Syndrome MKB Type and MED12 Mutations
(A) Photographs of individuals with MED12 mutations: family 1 proband (III-1) in infancy (Aa and Ac) and at age 4 years (Ab) and
family 1 uncle (II-3) at age 4 years (Ad) and 18 years (Ae and Af); family 2 proband (II-1) at ages 1 year (Ag), 9 years (Ah), and 15 years
(Ai) and family 2 brother (II-2) at ages 1 month (Aj), 7 years (Ak), and 13 years (Al); and family 3 proband (II-1) at ages 3 years (Am),
10 years (An), and 16 years (Ao). Beside the photographs, the electropherograms show the mutation in bold of an affected individual
(top) and a control (bottom), and the pedigrees show results of segregation analysis. Mutant alleles are represented by a plus sign (þ),
and wild-type alleles are represented by a minus sign (–).
(B) Schematic overview of MED12, including the PQL domain, which is involved in b-catenin and GLI3 binding,5,6 shows previously
published amino acid changes leading to Opitz-Kaveggia syndrome7,8 and Lujan-Fryns syndrome9 and the presently identified amino
acid changes leading to Ohdo syndrome MKB type.lymphoblastoid cell line of the nephew because both he
and his uncle were deceased; for family 2, DNA was iso-
lated from peripheral blood of the proband according to
standard procedures. Exome enrichment was performed
with the SureSelect Human All Exon 50 Mb Kit (Agilent
Technologies, Santa Clara, CA, USA). Sequencing was per-
formed on the SOLiD 5500xl sequencer (Life Technologies,
Carlsbad, CA, USA). Reads were aligned to the UCSC
Genome Browser hg19 reference genome with the use of
Life Technologies LifeScope software version 2.1. Ninety-
two percent of the X chromosomal exons were covered
at least three times on average in both individuals. Variants
were annotated with a custom pipeline.12 Only nonsynon-
ymous changes in the coding regions or changes affecting
the canonical splice sites were analyzed. Variants present
in dbSNP132 or in our in-house database containing data
of 368 exomes were excluded. Assuming a hemizygous X
chromosomal change, we only considered variants that
were present in at least 70% of the reads on the X chromo-
some (Table S2). After this selection, four and five variants
remained in families 1 and 2, respectively (Tables S2 and
S3). Only one gene showed a private nonsynonymous
variant in both families; this gene was mediator com-
plex subunit 12 (MED12 [MIM 300188]; RefSeq accession402 The American Journal of Human Genetics 92, 401–406, March 7number NM_005120.2), which encodes mediator of RNA
polymerase II transcription subunit 12. Each individual
had a missense mutation: c.3443G>A (p.Arg1148His) or
c.3493T>C (p.Ser1165Pro). Sanger sequencing confirmed
the presence of the mutation and showed segregation of
the mutation with the disorder in the families (Figure 1).
We subsequently performed Sanger sequencing of all
45 coding exons of MED12 on DNA from nine simplex
male persons with the clinical diagnosis of Ohdo syn-
drome. Primer sequences and conditions are available
upon request. In this cohort, we detected one additional
MED12 missense mutation (c.5185C>A [p.His1729Asn]),
which was shown to be de novo, in a person with the
MKB type. All three missense mutations in MED12 affect
evolutionary highly conserved amino acids and were pre-
dicted to be damaging to protein function (Table 1). The
amino acid change p.His1729Asn is situated within the
PQL domain of MED12, and the other two amino acid
changes, p.Arg1148His and p.Ser1165Pro, are not situated
in a known domain. The occurrence of three different
hemizygous missense mutations in three unrelated fami-
lies affected by Ohdo syndrome MKB type shows that
mutations in MED12 are the underlying cause of this
X-linked form of Ohdo syndrome. Of note, a second, 2013





(RefSeq NP_005111.2) PhyloPb PolyPhen-213 SIFT14 Reference
Ohdo Syndrome Maat-Kievit-Brunner (MKB) Type
chrX: 70,348,536 c.3443G>A p.Arg1148His 5.0 probably damaging deleterious family 1
chrX: 70,348,981 c.3493T>C p.Ser1165Pro 4.3 probably damaging deleterious family 2
chrX: 70,356,290 c.5185C>A p.His1729Asn 5.4 probably damaging deleterious family 3
Opitz-Kaveggia Syndrome
chrX: 70,347,217 c.2881C>T p.Arg961Trp 5.6 probably damaging deleterious Risheg7
chrX: 70,347,209 c.2873G>A p.Gly958Glu 2.8 probably damaging deleterious Rump8
Lujan-Fryns Syndrome
chrX: 70,347,781 c.3020A>G p.Asn1007Ser 3.1 probably damaging deleterious Schwartz9
aUCSC Genome Browser hg19.
bBased on 46 vertebrate species.segregating change was identified in family 2: c.4638A>C
(p.Lys1546Asn) in alpha-thalassemia/mental retardation
syndrome X-linked (ATRX [MIM 300032]; RefSeq NM_
000489.3), mutations in which can cause ATRX syndrome
(MIM 301040) (Table S3). This change is not present in
any of the available databases. It was predicted to be
detrimental to protein function by PolyPhen-2 and to
be neutral according to SNPs&GO.13,15 For the proband,
hematological analysis including high-performance liquid
chromatography and capillary electrophoresis16,17 showed
no indication of alpha-thalassemia. In addition, HbH in-
clusions were absent in over 2,000 cells (data not shown).
This does not support pathogenicity of the mutation,
although it does not exclude ATRX syndrome because
HbH inclusions are not seen in 12% of persons with
ATRX syndrome.18 In combination with the facial dysmor-
phisms that differ from those of ATRX syndrome and over-
lap with those of the other families affected by MED12
mutations (Figure 1), this strongly suggests that the muta-
tion in MED12 is the main cause of the phenotype in
family 2. However, we cannot exclude an additional effect
of the ATRXmutation on the family 2 phenotype, which is
at the relatively severe end of the spectrum associated with
MED12 mutations.
Specific mutations at different positions in MED12 have
previously been reported in Opitz-Kaveggia syndrome (or
FG syndrome) (MIM 305450) and Lujan-Fryns syndrome
(MIM 309520).7–9 Currently, ten families affected by
Opitz-Kaveggia syndrome and the recurrent amino acid
substitution p.Arg961Trp19 and one family affected by
a p.Gly958Glu change8 have been described, whereas
the p.Asn1007Ser substitution has been described in two
families affected by Lujan-Fryns syndrome.9 Clinically,
clear differences can be seen between Ohdo syndrome
and these two syndromes (Figure S1). In contrast to the
facial features associated with Opitz-Kaveggia and Lujan-
Fryns syndrome, ptosis, blepharophimosis, a bulbous nasal
tip, a long philtrum, and maxillar hypoplasia with fullThe Amecheeks are unique to Ohdo syndrome. Moreover, dental
anomalies and hearing loss are frequent, whereas anal mal-
formations, agenesis of the corpus callosum, and macro-
cephaly are not present in the individuals with Ohdo
syndrome. Overlapping characteristics are the following
relatively nonspecific features: ID, hypotonia, behavioral
problems, and some facial dysmorphisms, mainly hyperte-
lorism, micrognathia, small low-set ears, and a high fore-
head, especially in family 3.
MED12 is a component of the multisubunit RNA
polymerase II transcriptional Mediator.20 This complex is
involved in transcriptional regulation by conveying infor-
mation from gene-specific regulatory elements to the
RNA polymerase II transcription machinery.21 Mediator
consists of four distinct modules.22,23 The head, middle,
and tail modules together form the core Mediator complex
that interacts directly with RNA polymerase II and both
general and gene-specific transcription factors.24 MED12,
along with MED13, CCNC, and CDK8, composes a fourth
‘‘kinase’’ module that reversibly associates with the core
complex.25 This module was primarily thought to be
involved in transcriptional repression through blocking
the binding of the core Mediator complex to RNA poly-
merase II because Mediator containing this module is less
active than Mediator lacking this module.23,26 However,
the kinase module was recently also found to be in-
volved in transcriptional activation.27 Through MED12,
the kinase module modulates, for example, Wnt/b-catenin
signaling5 and Gli3-dependent sonic hedgehog sig-
naling.6,28 In addition, MED12 is involved in epigenetic
silencing of neuronal gene expression imposed by the
RE1-silencing transcription factor REST.29 In this regard,
we previously showed that the MED12 interface in
Mediator links REST with euchromatic histone-lysine
N-methyltransferase 2 (EHMT2) in epigenetic repression
of neuronal genes in nonneuronal cells.29 Importantly,
we also found that the MED12 mutations identified
in Opitz-Kaveggia and Lujan-Fryns syndrome disruptedrican Journal of Human Genetics 92, 401–406, March 7, 2013 403
Figure 2. Ohdo Syndrome Mutations in MED12 Disrupt Its Gene-Repression Function
(A) HEK293 cells were transfected with control (siCNTL) or MED12-specific (siMED12) siRNAs. Where indicated (FLAG-MED12),
MED12-knockdown cells were transfected with FLAG-tagged siRNA-resistant WT, p.Arg1148His (R1148H), or p.Ser1165Pro (S1165P)
MED12 expression plasmids. RNA-expression levels of CHRM4, SNAP25, or SYN1were determined by quantitative RT-PCR. mRNA levels
are expressed relative to mRNA levels in control siRNA-transfected cells. Data represent the mean5 the SEM of at least three indepen-
dent experiments performed in duplicate. Asterisks denote statistically significant differences compared to WT FLAG-MED12 (Student’s
t test, *p< 0.05, **p< 0.01). FLAG-taggedMED12mutants p.Arg1148His and p.Ser1165Pro were unable to repress CHRM4, SNAP25, and
SYN1 expression.
(B) Nuclear extracts5 from a representative transient expression assay were resolved by SDS-PAGE and processed by immunoblot analysis
with antibodies specific to MED12, the FLAG epitope on FLAG-MED12 derivatives, or the TFIIEb that was used as an internal loading
control. Representative immunoblots show that siMED12 significantly diminished expression of MED12. Cotransfection with FLAG-
MED12 restored MED12 expression for the WT and both mutants. For the doublet bands, the band with the higher molecular mass
was previously shown to represent full-length MED12.28 The relative levels of ectopically expressed FLAG-MED12 WT and mutant
proteins averaged over four independent experiments are given below the immunoblots and were calculated first by normalization
of FLAG-MED12 immunoblot signals to internal-control TFIIEb signals (within the linear range of detection; Figure S2) and subsequent
division of the normalized expression levels of FLAG-MED12 mutants by those of FLAG-MED12 WT. Immunoblot signals were quanti-
fied with ImagQuant TL software. No statistically significant differences in expression levels were observed (Student’s t test; p values are
given above the bars).
(C) Nuclear extracts from untransfected (CNTL) or transfected HEK293 cells transiently expressing FLAG epitope-tagged WT,
p.Arg1148His, or p.Ser1165Pro MED12 derivatives were subjected to immunoprecipitation (IP) with IgG or antibodies specific to
MED30, as indicated. Mediator immunoprecipitates were resolved by SDS-PAGE and processed by immunoblot analysis with antibodies
specific to the FLAG epitope or the indicated Mediator subunits. Input corresponds to 10% of the nuclear extracts subjected to IP. FLAG-
tagged MED12 mutants p.Arg1148His and p.Ser1165Pro were incorporated into Mediator comparably to WT MED12.
(D) HA-tagged G9a was expressed without or with FLAG-tagged MED12WT, p.Arg1148His, or p.Ser1165Pro derivatives in HEK293 cells
prior to the processing of nuclear extracts by IP with antibodies specific to the HA epitope. Immunoprecipitates were resolved by SDS-
PAGE and processed by immunoblot analysis with FLAG- or HA-specific antibodies, as indicated. Input corresponds to 10% of the
nuclear extracts subjected to IP. FLAG-taggedMED12mutants p.Arg1148His and p.Ser1165Pro bound to G9a comparably toWTMED12.REST-imposed extraneuronal gene silencing by impairing
REST-directed recruitment of Mediator to RE1-silencing
elements.29
To explore the pathogenicity of the MED12 missense
mutations identified in Ohdo syndrome, we monitored
the impact of two of the three identified mutations on
repression of REST target genes. To this end, we compara-
tively examined siRNA-resistant wild-type (WT) FLAG-
tagged MED12 (FLAG-MED12) and its corresponding
p.Arg1148His and p.Ser1165Pro mutant derivatives for
their respective abilities to suppress enhanced REST-
target-gene expression triggered by RNAi-mediated deple-404 The American Journal of Human Genetics 92, 401–406, March 7tion of endogenous MED12 in HEK293 cells (Figure 2).
As expected, MED12 knockdown triggered derepression
of REST target genes, including cholinergic receptor,
muscarinic 4 (CHRM4 [MIM 118495]), synaptosomal-
associated protein, 25 kDa (SNAP25 [MIM 600322]), and
synapsin I (SYN1 [MIM 313440]). Introduction of WT
FLAG-MED12 in these cells reversed this effect; in con-
trast, the p.Arg1148His and p.Ser1165Pro mutants were
significantly compromised in this ability (Figure 2A). This
indicates that the MED12 mutations in Ohdo syndrome
impair the repressive function of MED12. Neither amino
acid change deleteriously affected the incorporation of, 2013
MED12 into Mediator (Figure 2C) or its direct interaction
with G9a (Figure 2D), indicating that the Ohdo syndrome
MED12 mutations do not disrupt the function of MED12
as a stable G9a interface in Mediator. It is thus possible
that the Ohdo syndrome mutations in MED12 impair
recruitment of Mediator to RE1-bound REST, as was shown
previously for the Opitz-Kaveggia and Lujan-Fryns muta-
tions in MED12.29 Impaired Mediator recruitment to RE1
elements could explain how these amino acid substitu-
tions disrupt REST-imposed epigenetic restrictions on neu-
ronal gene expression, given that MED12 and/or Mediator
is essential to link RE1-bound REST with EHMT2.
It is of particular interest that MED12 is implicated in
chromatin modification through H3K9 methylation,
given that Ohdo syndrome SBBYS type has recently been
shown to be caused by mutations in KAT6B, a component
of the MOZ/MORF complex that has histone H3 acetyl-
transferase activity.30 Apart from their role in Ohdo
syndrome, both MED12 and KAT6B have also been impli-
cated in tumor development. In acute myeloid leukemia,
translocations leading to a fusion gene of KAT6B and
opsin 1 (cone pigments) long-wave-sensitive have been
identified,31 and MED12 mutations have recently been
identified in prostate cancer.32 With that in mind, it is
noteworthy that one of our family members died of pros-
tate cancer at the age of 25 years. Moreover, both genes
are implicated in uterine leiomyomata. KAT6B was
previously mapped to the breakpoint of recurrent 10q22
aberrations,33 which are present in 2% of uterine leiomyo-
mata,34 and exon 2 ofMED12 is mutated in 70% of uterine
leiomyomata.35 For uterine leiomyomata, involvement of
other genes has been suggested, but only a few have
been identified.36 Therefore, the observation that both
MED12 and KAT6B are chromatin-modifying enzymes
implicated in Ohdo syndrome and the development of
uterine leiomyomata and other tumors strongly suggests
that both genes are functionally related.
Ohdo syndrome, especially SBBYS type, is generally
considered a de novo dominant disorder with a low recur-
rence risk. Our study shows that Ohdo syndrome can also
be an X-linked disorder. Moreover, by screening only
nine simplex male individuals with Ohdo syndrome, we
identified one additional pathogenic MED12 mutation.
Although Ohdo syndrome MKB type can be distinguished
from Ohdo syndrome SBBYS type at older age through the
triangular face and the increasingly bulbous nose with
thick alae nasi, its facial phenotype can be very similar to
that of Ohdo syndrome SBBYS type at a young age. There-
fore, we recommend sequencing of MED12 in all young
male individuals with Ohdo syndrome because this can
have great implications for the recurrence risk in the
respective families.
In conclusion, we show that mutations in MED12 cause
X-linked Ohdo syndrome. The identification of this gene
in Ohdo syndrome, together with KAT6B, points to aber-
rant chromatinmodification as central to the pathogenesis
of Ohdo syndrome.The AmeSupplemental Data
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